References
[1] Barouch DH. Covid-19 Vaccines — Immunity, Variants, Boosters.
New England Journal of Medicine 2022;387(11):1011-20.
[2] Bhimraj A MR, Shumaker AH, Baden L, Cheng VC, Edwards KM,
Gallagher JC, Gandhi RT, Muller WJ, Nakamura MM, O’Horo JC, Shafer RW,
Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious
Diseases Society of America Guidelines on the Treatment and Management
of Patients with COVID-19. 2022.
[3] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral
GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science
translational medicine 2017;9(396).
[4] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the
Treatment of Covid-19 - Final Report. The New England journal of
medicine 2020;383(19):1813-26.
[5] Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral
Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New
England journal of medicine 2021; 384(6):497-511.
[6] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe
COVID-19: a randomised, double-blind, placebo-controlled, multicentre
trial. Lancet (London, England) 2020;395(10236):1569-78.
[7] Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir
vs Standard Care on Clinical Status at 11 Days in Patients With Moderate
COVID-19: A Randomized Clinical Trial. Jama 2020;324(11):1048-57.
[8] Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to
Prevent Progression to Severe Covid-19 in Outpatients. New England
Journal of Medicine 2021;386(4):305-15.
[9] Rubin D, Chan-Tack K, Farley J, Sherwat A. FDA Approval of
Remdesivir — A Step in the Right Direction. New England Journal of
Medicine 2020;383(27):2598-600.
[10] Razonable RR, Ganesh R, Bierle DM. Clinical Prioritization of
Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19.
Mayo Clin Proc 2022;97(1):26-30.
[11] Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of
the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine
2020;384(5):403-16.
[12] Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of
the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine
2020;383(27):2603-15.
[13] Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. New England
Journal of Medicine 2020;383(25):2451-60.
[14] Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors
associated with COVID-19-related death using OpenSAFELY. Nature
2020;584(7821):430-6.
[15] Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR.
Risk Factors Associated With Mortality Among Residents With Coronavirus
Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada.
JAMA Network Open 2020;3(7): e2015957-e.
[16] Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip
GYH. Comorbidities associated with mortality in 31,461 adults with
COVID-19 in the United States: A federated electronic medical record
analysis. PLoS medicine 2020;17(9):e1003321.
[17] Razonable RR, Aloia NCE, Anderson RJ, et al. A Framework for
Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk
Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic
Model. Mayo Clin Proc 2021;96(5):1250-61.
[18] Ranganath N, O’Horo JC, Challener DW, et al. Rebound Phenomenon
after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in
High-Risk Persons. Clin Infect Dis 2022; [published online ahead of
print] doi: 10.1093/cid/ciac481.
[19] Haddad TC, Coffey JD, Deng Y, et al. Impact of a High-Risk,
Ambulatory COVID-19 Remote Patient Monitoring Program on Utilization,
Cost, and Mortality: Mayo Clin Proc. 2022; [published online ahead of
print] doi: 10.1016/j.mayocp.2022.08.015.